Neoleukin Therapeutics, Inc. (NLTX): Price and Financial Metrics

Neoleukin Therapeutics, Inc. (NLTX): $0.60

0.02 (+2.60%)

POWR Rating

Component Grades













Add NLTX to Watchlist
Sign Up

Industry: Biotech



in industry

NLTX Stock Price Chart Interactive Chart >

Price chart for NLTX

NLTX Price/Volume Stats

Current price $0.60 52-week high $3.84
Prev. close $0.58 52-week low $0.38
Day low $0.58 Volume 42,115
Day high $0.60 Avg. volume 133,816
50-day MA $0.49 Dividend yield N/A
200-day MA $0.84 Market Cap 25.34M

Neoleukin Therapeutics, Inc. (NLTX) Company Bio

Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company. The Company develops medicines to treat serious diseases, including cancer, inflammatory, and autoimmune disorders.

NLTX Latest News Stream

Event/Time News Detail
Loading, please wait...

NLTX Latest Social Stream

Loading social stream, please wait...

View Full NLTX Social Stream

Latest NLTX News From Around the Web

Below are the latest news stories about NEOLEUKIN THERAPEUTICS INC that investors may wish to consider to help them evaluate NLTX as an investment opportunity.

Neoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at American Society of Hematology (ASH) Annual Meeting

Targeted, precision-tuned agonist of IL-2 receptor selectively expands regulatory T cellsSEATTLE, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today presented data on NEO-TRA1, a precision-tuned agonist of the IL-2 receptor beta and gamma subunits that is targeted to and selectively expands inhibitory T-regulatory cells. The data are bein

Yahoo | December 12, 2022

Neoleukin (NLTX) Stops Development of Lead Drug, Stock Down

Due to discontinuing the development of its lead candidate, Neoleukin (NLTX) has no pipeline candidates in clinical development. Management undertakes restructuring initiatives to curb cash burn.

Yahoo | November 16, 2022

Mizuho Securities downgrades Neoleukin Therapeutics (NLTX) to a Hold

In a report released today, Mara Goldstein from Mizuho Securities downgraded Neoleukin Therapeutics (NLTX - Research Report) to a Hold, with a price target of $2.00. The company's shares closed yesterday at $0.53.Goldstein covers the Healthcare sector, focusing on stocks such as Incyte, Merck & Company, and Adaptimmune Therapeutics. According to TipRanks, Goldstein has an average return of 1.1% and a 36.65% success rate on recommended stocks. Neoleukin Therapeutics has an analyst consensus of Hold, with a price target consensus of $3.00.

Carrie Williams on TipRanks | November 15, 2022

Neoleukin Pauses Development Of NL-201, Cuts 40% Of Employee Strength

Neoleukin Therapeutics Inc (NASDAQ: NLTX) announced discontinuing the development of NL-201 for strategic reasons. Preliminary monotherapy data from the Phase 1 study of NL-201 did not demonstrate significant immunogenicity even after multiple cycles of therapy. The data demonstrated engagement of the target receptor's expected pharmacodynamic changes for a potent IL-2/IL-15 agonist. In April, the FDA removed the clinical hold related to Neoleukin's investigational new drug application to begin

Yahoo | November 15, 2022

Neoleukin Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Update

-- Development of NL-201 to be discontinued for strategic reasons ---- Company to focus on next-generation de novo proteins and core technology ---- Company restructuring to extend cash runway into the second half of 2025 -- SEATTLE, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for the third quarter ended

Yahoo | November 14, 2022

Read More 'NLTX' Stories Here

NLTX Price Returns

1-mo 17.88%
3-mo 6.57%
6-mo -43.93%
1-year -83.19%
3-year -95.15%
5-year -95.40%
YTD 17.88%
2022 -89.44%
2021 -65.82%
2020 14.45%
2019 470.37%
2018 -81.63%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7126 seconds.